Nucliq Biologics

What Nucliq Biologics does

Nucliq Biologics is a privately held Canadian biotech founded in 2019 and headquartered in St. John's, Newfoundland and Labrador. The company builds microbiome-based diagnostics and therapeutics anchored on two proprietary assets: Gutcheck, a DNA-sequencing consumer microbiome test launched in 2022 under a Health Canada MDEL class I license, and Microterra AI, an in-house multi-omics and machine learning platform that analyzes Gutcheck-derived metagenomic, transcriptomic, and metabolomic data to identify therapeutic targets. Nucliq monetizes its diagnostic offering primarily through direct-to-consumer sales via mygutcheck.ca and, since 2025, through a payer channel with Medavie Blue Cross making it the first insurer-covered gut health program in Canada. A women's-health-focused variant, Gutcheck VIVO (estrobolome and hormone analysis), was introduced in 2025, alongside expansions to the United States and bilingual English/French service availability in Canada.

The company operates a wholly-owned Indian subsidiary (Nucliq Biologics India Pvt Ltd, established 2024) supporting R&D and B2B collaborations. Its Microterra AI drug discovery pipeline carries four Discovery-stage candidates targeting depression (NBD-256), IBD (NBD-165), asthma (NBD-342), and psoriasis (NBD-002), addressing gut-brain, gut-lung, and gut-skin axes. Revenue is generated through one-time test kit sales and recurring insurance-covered testing, plus B2B contracts with healthcare networks and research institutions; a 2021 HREA-approved pilot study of 75 participants completed before commercial launch. The company has been primarily funded through non-dilutive Canadian federal (NRC, ACOA, NRC-IRAP) and provincial (Government of Newfoundland and Labrador) grants and loans, with cumulative disclosed funding of approximately CAD $725,000. Nucliq is led by co-founders Dr. Nikita Kendyala (CEO) and Dr. Purvikalyan Pallegar (CTO), both Memorial University of Newfoundland doctoral alumni, supported by a Scientific and Clinical Advisory Board with academic and clinical ties to Memorial University and SWASA Hospitals India.

Name

Nucliq Biologics

Legal name

Nucliq Biologics Inc.

Website

https://nucliqbio.ca

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Nucliq Biologics is a Canadian biotech that develops and sells Gutcheck, a DNA-based consumer microbiome test, and Microterra AI, a multi-omics drug discovery platform targeting depression, IBD, asthma, and psoriasis, serving consumers, insurers, and clinical researchers across Canada, the U.S., and India.

Ownership category

akta.pro rank

Product category

Microbiome Diagnostics and Precision Therapeutics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Microbiome diagnostics
• Gut health testing
• Multi-omics analysis
• Precision therapeutics
• AI drug discovery

Headquarters

HQ city

St. John's

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Direct-to-Consumer Microbiome Testing: Consumer microbiome tests (Gutcheck, Gutcheck VIVO) sold directly to individuals, offering personalized gut health insights and food-based recommendations. Revenue generated through test kit sales and analysis services.
2. Insurance-Covered Gut Health Program: Partnership with Medavie Blue Cross to provide gut health testing to eligible insurance members. Tests covered through insurance digital platform, creating recurring revenue through insured populations.
3. B2B Partnerships: B2B partnerships in Canada providing microbiome testing services to healthcare networks, wellness centers, and institutional partners. Revenue through bulk testing agreements and institutional contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Nucliq Biologics develops and sells Gutcheck, Canada's first DNA-based consumer microbiome test that delivers personalized gut health insights and food-based recommendations, and Gutcheck VIVO, a women's health-focused microbiome test with estrobolome analysis. The company also operates Microterra AI, a proprietary AI and multi-omics drug discovery platform that identifies bioactive metabolites and therapeutic targets across gut-brain, gut-lung, gut-skin, and gut-immune axes, supporting a pipeline of precision therapeutic candidates.

Product overview

Nucliq Biologics is a health tech company offering a portfolio of microbiome-based products and services. The core offering is Gutcheck, Canada's first consumer microbiome test using DNA sequencing, with two main variants: Gutcheck (general) and Gutcheck VIVO (women's health-focused). Built on this diagnostic foundation, the company operates Microterra AI, an AI-powered drug discovery platform that analyzes microbiome data to advance precision therapeutics across four programs targeting depression (NBD-256), IBD (NBD-165), asthma (NBD-342), and psoriasis (NBD-002). The Nucliq Research Initiative supports clinical research across gut-brain, gut-lung, and gut-skin axes. The company expanded internationally with a subsidiary in India and launched services in the USA in 2025.

Differentiator

Problem solved

Functional benefit

Brands

• Gutcheck: Canada's first comprehensive microbiome test offering personalized gut health insights and food-based recommendations using cutting-edge DNA sequencing
• Gutcheck VIVO
• Microterra AI

Products and services

• Gutcheck Canada's first comprehensive DNA-based microbiome test that delivers personalized gut health insights and food-based recommendations by analyzing gut bacteria through cutting-edge DNA sequencing. Targeted at individual consumers and athletes seeking digestive, fatigue, brain fog, and performance optimization.
• Gutcheck VIVO First-of-its-kind microbiome test designed exclusively for women that analyzes how gut health affects estrogen balance, skin, fertility, mood, metabolism, and more across every life stage, featuring unique estrobolome and hormone-focused analysis.
• Microterra AI AI-powered drug discovery platform that transforms Gutcheck-derived microbiome insights and multi-omics data into precision therapeutic candidates, decoding complex microbial ecosystems to identify bioactive metabolites and novel therapeutic targets across neurological, gastrointestinal, immune, and skin conditions.
• Nucliq Research Initiative Research program running multi-site clinical trials exploring the gut-brain axis (autism/ADHD), gut-lung axis (asthma/allergies), and gut-skin axis (psoriasis) using the Gutcheck platform with autism-focused schools and healthcare networks.

Quantifiable outcome

• Canada's first consumer microbiome test - Gutcheck launched 2022
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

One partnership is on record.

• Medavie Blue CrosscoreChannel Partner/ Reseller/ Distributor · 28 November 2025Medavie Blue Cross became the first insurer in Canada to offer comprehensive gut health testing to members through Nucliq Biologics' DNA microbiome tests. The program combines dietitian services with personalized gut health insights, improving preventive health access for eligible members through its digital platform.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Viome: Viome is the leading direct-to-consumer microbiome testing brand globally, using metatranscriptomic AI analysis to produce personalized nutrition recommendations. It is the closest analog to Nucliq's Gutcheck product in business model, technology, and target customer.
• DayTwo: DayTwo offers microbiome-based personalized nutrition through both consumer and B2B channels, including partnerships with health plans and providers. Comparable to Nucliq's Gutcheck + Medavie distribution model.
• Atlas Biomed: Atlas Biomed sells consumer DNA and microbiome test kits with personalized health recommendations in Europe. It is comparable on product offering and DTC GTM approach, though operating in a different geography.
• Biohm: Biohm offers consumer microbiome testing combined with probiotic and digestive enzyme products. Comparable product breadth to Nucliq's Gutcheck, including gut health personalization for consumers.

Broad incumbents

• Thorne: Thorne is a broader wellness and supplement brand that has incorporated microbiome insights into personalized health recommendations. It is a broad incumbent competing with Nucliq in the personalized wellness category rather than specializing in microbiome.
• Seres Therapeutics: Seres is a clinical-stage microbiome therapeutics company that has taken microbiome-derived drug candidates into late-stage trials. It is a broad incumbent in microbiome drug discovery, comparable to Nucliq's Microterra AI pipeline at much larger scale.
• Finch Therapeutics: Finch was a clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota products for GI and metabolic conditions (now winding down). A historical peer for comparing the GI-axis therapeutic direction of Nucliq's pipeline.

Emerging players

• Vedanta Biosciences: Vedanta is a clinical-stage company engineering defined bacterial consortia as therapeutics for GI and immune conditions. Comparable on the microbiome drug discovery side of Nucliq's business (e.g., NBD-165 IBD program).
• Eligo Bioscience: Eligo develops engineered phage-based microbiome therapeutics, with technology overlap to Nucliq's bioinformatic approach to microbe-host interaction. Relevant peer for the AI/ML-enabled microbiome drug discovery trajectory.

Regional players

• MaaT Pharma: MaaT Pharma is a European clinical-stage microbiome therapeutics company developing standardized fecal microbiota products for GI and oncology indications. A regional peer with overlapping therapeutic focus to Nucliq's IBD pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/nucliqb
• YouTubeyoutube.com/@gutcheck2995
• Facebookfacebook.com/mygutcheck
• Instagraminstagram.com/mygutcheck

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucliq Biologics